Rapid quantification assay of hepatitis B virus DNA in human serum and plasma by Fully Automated Genetic Analyzer μTASWako g1
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0278143 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Moto Watanabe und 2 weiteren Autor:innen. Beteiligte Einrichtung: Diagnostics Research Laboratories, FUJIFILM Wako Pure Chemical Corporation, Amagasaki, Hyogo, Japan. Hauptthemen laut MEDLINE: Hepatitis B, Hepatitis B, Chronic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fujifilm Wako Pure Chemical Corporation.
Abstract (Originalsprache)
Real-time monitoring of serum hepatitis B virus (HBV) levels is essential for the management of patients with chronic HBV infection in clinical practice, including monitoring the resistance of anti-HBV nucleotide analog or the detection of HBV reactivation. In this context, serum HBV deoxyribonucleic acid (DNA) quantification should be rapidly measured. A rapid HBV DNA quantification assay was established on the Fully Automated Genetic Analyzer, μTASWako g1. The assay performs automated sample preparation and DNA extraction, followed by the amplification and detection of quantitative polymerase chain reaction (PCR) combined with capillary electrophoresis (qPCR-CE) on integrated microfluidic chip. This study aimed to evaluate the analytical and clinical performance of HBV DNA assay on the μTASWako g1 platform in human serum and EDTA-plasma. The HBV DNA assay has a linear quantitative range from 20 to 10 8 IU/mL of HBV DNA with standard deviation (SD) of ≤0.14 log 10 IU/mL. The limits of detection of the assay were 4.18 for the serum and 4.35 for EDTA-plasma. The HBV assay demonstrated the equivalent performance in both human serum and EDTA-plasma matrices. The HBV genotypes A to H were detected with an accuracy of ±0.34 log 10 IU/mL. In quantification range, the HBV DNA assay was correlated with Roche cobas AmpliPrep/cobas TaqMan Ver2.0 (CAP/CTM v2) ( r = 0.964). The mean difference (μTASWako g1–CAP/CTM v2) of the reported HBV DNA was −0.01 log 10 IU/mL. Overall, the sensitivity, accuracy, and precision of the μTASWako g1 HBV assay were comparable to the existing commercial HBV DNA assay, and the assay can be completed within 110 min. This evaluation suggests that the HBV DNA assay on the μTASWako g1 is potentially applied for alternative method of the HBV viral load test, in particular with the advantage of the HBV DNA result availability within 2 h, improving the HBV infection management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Diagnostics Research Laboratories, FUJIFILM Wako Pure Chemical Corporation, Amagasaki, Hyogo, Japan.
- Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Gifu, Japan.
- Department of Diagnostics Development, FUJIFILM Wako Pure Chemical Corporation, Chuo-Ku, Tokyo, Japan.
ORCID-Profile: Hidenori Toyoda, Tomohisa Kawabata
Förderung
- Fujifilm Wako Pure Chemical Corporation
Zitieren
APA
Watanabe, M., Toyoda, H., & Kawabata, T. (2023). Rapid quantification assay of hepatitis B virus DNA in human serum and plasma by Fully Automated Genetic Analyzer μTASWako g1. PLOS ONE. https://doi.org/10.1371/journal.pone.0278143
Vancouver
Watanabe M, Toyoda H, Kawabata T. Rapid quantification assay of hepatitis B virus DNA in human serum and plasma by Fully Automated Genetic Analyzer μTASWako g1. PLOS ONE. 2023. doi:10.1371/journal.pone.0278143
BibTeX
@article{Watanabe2023,
author = {Watanabe, Moto and Toyoda, Hidenori and Kawabata, Tomohisa},
title = {Rapid quantification assay of hepatitis B virus DNA in human serum and plasma by Fully Automated Genetic Analyzer μTASWako g1},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0278143}
}
EUVIMED